T-DM1 Clinical Trials

4 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: Kadcyla, ado-trastuzumab emtansine, trastuzumab emtansine

Pipeline

Phase 2: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

University of Virginia1
Sichuan Baili Pharmaceutical Co., Ltd.1
GeneQuantum Healthcare (Suzhou) Co., Ltd.1
Dana-Farber Cancer Institute1

Indications

Breast Cancer4
Cancer4
HER2-positive Breast Cancer3
Stage IV Breast Cancer1
Estrogen Receptor-positive Breast Cancer1

Other2 trials

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Phase 3

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Phase 3

Boston, Massachusetts1 trial

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2

Charlottesville, Virginia1 trial

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

University of Virginia

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.